Home > Journals > Minerva Biotecnologica > Past Issues > Minerva Biotecnologica 2008 September;20(3) > Minerva Biotecnologica 2008 September;20(3):133-5

CURRENT ISSUE
 

ARTICLE TOOLS

Reprints

MINERVA BIOTECNOLOGICA

A Journal on Biotechnology and Molecular Biology


Indexed/Abstracted in: EMBASE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,246


eTOC

 

TECHNICAL NOTES  


Minerva Biotecnologica 2008 September;20(3):133-5

language: English

A simultaneous dual-isotope acquisition and imaging fusion protocol in nuclear medicine: 111In-Octreotide SPECT and 99mTc-HMDP bone SPECT

Zanotti-Fregonara P. 1, Keller I. 2, Devaux J.-Y. 2, Massaro A. 3, Rubello D. 3, Hindié E. 4

1 DSV/IBM/SHFJ/LIME Commissariat à l’Energie Atomique, Orsay, France
2 Service de Médecine Nucléaire Hôpital St Antoine, Paris, France
3 Department of Nuclear Medicine PET Center, S. Maria della Misericordia Hospital, Rovigo, Italy
4 Service de Médecine Nucléaire, Hôpital St Louis, Paris, France


FULL TEXT  


In the present preliminary study, we developed a protocol for the acquisition and fusion of dual-isotope tomographic (SPECT) images (111In-Octreotide SPECT and 99mTc-HMDP SPECT). This procedure was performed in ten consecutive patients, and the first results were encouraging: it proved to be a simple and accurate method to improve the anatomic localization of 111In-Octreotide SPECT positive foci for the staging and follow-up of tumours expressing somatostatin receptors (Octreotide is an analog of somatostatin), particularly in discriminating bone metastases from soft tissue metastases located near to bone itself.

top of page

Publication History

Cite this article as

Corresponding author e-mail